Pay in 4 interest-free payments of $6.34 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Analyses from a substudy of a previous Phase 3 trial (NCT03882970) involving diabetic patients showed that tirzepatide led to a reduction in liver fat content, marking it as a possible treatment for fatty liver disease
Curr Pharm Biotechnol 25(7):807824 Gholampour F, Mohammadi Z, Karimi Z, Owji SM (2020) Gene protective effect of genistein in a rat model of ischemic acute kidney injury
In the SURPASS-2 trial, patients on tirzepatide 15mg lost 13.1% body weight compared to 6.7% with semaglutidenearly double the loss
The biosynthetic mechanisms for synthetases use energy from nucleoside triphosphates, whereas synthases do not
Obesity is a major risk factor for many chronic conditions like type 2 diabetes and cardiovascular diseases
US$ 20.88
US$ 22.32
US$ 22.17
US$ 24.44
US$ 27.52
US$ 25.77
US$ 21.89
